Overview

Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome

Status:
Completed
Trial end date:
2020-09-24
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety, efficacy/pharmacodynamics (PD) and pharmacokinetics (PK) of teduglutide treatment in infants with short bowel syndrome (SBS) dependent on parenteral (PN) support.
Phase:
Phase 3
Details
Lead Sponsor:
Shire
Treatments:
Teduglutide